Definium Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	84.34	48.64	38.62	41.74	30.16	58.77
Research & Development	169.81	117.67	65.3	52.12	36.17	34.79
Operating Expenses	254.15	166.31	103.92	93.87	66.33	93.55
Operating Income	-254.15	-166.31	-103.92	-93.87	-66.33	-93.55
Interest Expense	-4.9	-5.48	-2.28	-0.92	-	-0.36
Interest & Investment Income	20.67	10.96	11.56	5.58	1.5	-
Currency Exchange Gain (Loss)	-0.12	-0.13	-0.64	0.16	0.2	-0.09
Other Non Operating Income (Expenses)	-98.98	-22.83	-15.94	-6.69	7.85	0.11
EBT Excluding Unusual Items	-337.48	-183.79	-111.22	-95.73	-56.8	-93.89
Merger & Restructuring Charges	-	-	-	-	-	-0.3
Other Unusual Items	-	-	2.54	-	-	-
Pretax Income	-337.48	-183.79	-108.68	-95.73	-56.8	-94.19
Income Tax Expense	-	-	-	-	-	-1.16
Net Income	-337.48	-183.79	-108.68	-95.73	-56.8	-93.04
Net Income to Common	-337.48	-183.79	-108.68	-95.73	-56.8	-93.04
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	114	89	70	39	31	27
Shares Outstanding (Diluted)	114	89	70	39	31	27
Shares Change	34.19%	26.78%	79.94%	26.90%	12.71%	54.25%
EPS (Basic)	-2.96	-2.06	-1.54	-2.44	-1.84	-3.40
EPS (Diluted)	-2.96	-2.06	-1.54	-2.44	-1.84	-3.40
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EBITDA	-	-166.28	-103.89	-	-66.32	-93.54
D&A For EBITDA	-	0.03	0.03	-	0.02	0.02
EBIT	-254.15	-166.31	-103.92	-93.87	-66.33	-93.55